Market Place
Sourcing Support
Gain Therapeutics Presents at Oppenheimer HCLS Conference
19 Feb 2026 //
GLOBENEWSWIRE
5 Investigational Therapies Revolutionizing Parkinson Landscape
26 Jan 2026 //
BIOSPACE
Gain Therapeutics at J.P. Morgan Healthcare Conference
07 Jan 2026 //
GLOBENEWSWIRE
Gain Therapeutics Backs GT-02287`s Disease-Modifying Potential
06 Jan 2026 //
GLOBENEWSWIRE
Gain Therapeutics Reports Positive Phase 1B Results For GT-02287
18 Dec 2025 //
GLOBENEWSWIRE
Gain Therapeutics Hosts Virtual KOL Event On GT-02287
18 Dec 2025 //
GLOBENEWSWIRE
Gain Therapeutics Presents Preclinical GT-02287 Data
20 Nov 2025 //
GLOBENEWSWIRE
Gain Therapeutics Reports Q3 2025 Financials & Corporate Update
12 Nov 2025 //
GLOBENEWSWIRE
Gain Therapeutics to Present at Neuroscience 2025
30 Oct 2025 //
GLOBENEWSWIRE
Gain Therapeutics To Attend The 2025 Maxim Growth Summit
16 Oct 2025 //
GLOBENEWSWIRE
Gain Therapeutics Hosts Virtual KOL Event On GT-02287
09 Oct 2025 //
GLOBENEWSWIRE
Gain Therapeutics Unveils GT-02287 Phase 1B Data In Parkinson
06 Oct 2025 //
GLOBENEWSWIRE
Gain Therapeutics Joins Drug Discovery Innovation Programme 2025
23 Sep 2025 //
GLOBENEWSWIRE
Gain Therapeutics Initiates GT-02287 Phase 1b Extension Study
18 Sep 2025 //
GLOBENEWSWIRE
Gain Therapeutics Q2 2025 Financial Results and Corporate Update
12 Aug 2025 //
GLOBENEWSWIRE
Gain Therapeutics to Speak at BTIG Biotechnology Conference
24 Jul 2025 //
GLOBENEWSWIRE
Gain Therapeutics Prices $7.0 Million Public Offering
16 Jul 2025 //
GLOBENEWSWIRE
Gain Therapeutics Proposes Public Offering
15 Jul 2025 //
GLOBENEWSWIRE
Gain Therapeutics Completes Enrollment in Ph 1b Parkinson’s Study
30 Jun 2025 //
GLOBENEWSWIRE
Gain Therapeutics to Participate in Upcoming Investor Conferences
10 Jun 2025 //
GLOBENEWSWIRE
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
29 May 2025 //
GLOBENEWSWIRE
Gain Therapeutics Reports Q1 2025 Financials and Corporate Update
14 May 2025 //
GLOBENEWSWIRE
Gain Therapeutics Presents Preclinical Data at IAPRD 2025
12 May 2025 //
GLOBENEWSWIRE
Gain Therapeutics to Attend Citizens Life Sciences Conference
01 May 2025 //
GLOBENEWSWIRE
Gain Therapeutics to Present Poster at IAPRD 2025 Congress
30 Apr 2025 //
GLOBENEWSWIRE
Gain`s Preclinical Data & Design of Phase 1b Study of GT-02287
10 Apr 2025 //
GLOBENEWSWIRE
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
28 Mar 2025 //
GLOBENEWSWIRE
Gain Therapeutics Reports Q4 and Year-End 2024 Financials Result
27 Mar 2025 //
GLOBENEWSWIRE
Gain Therapeutics Doses First Participant in GT-02287 Trial
14 Mar 2025 //
ACCESSWIRE
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
06 Mar 2025 //
GLOBENEWSWIRE
Gain Therapeutics CEO Gene Mack Issues Shareholder Update
06 Feb 2025 //
GLOBENEWSWIRE
Gain Therapeutics To Participate in Upcoming Investor Conferences
05 Feb 2025 //
GLOBENEWSWIRE
Gain Therapeutics Forms Advisory Board For Lead Drug GT-02287
08 Jan 2025 //
GLOBENEWSWIRE
Gain Therapeutics Names Gene Mack As CEO And Director
07 Jan 2025 //
GLOBENEWSWIRE
Gain Therapeutics Initiates Ph 1b Trial for GT-02287 in Parkinson’s
23 Dec 2024 //
GLOBENEWSWIRE
Gain Therapeutics To Present At Biotech Showcase 2025
11 Dec 2024 //
GLOBENEWSWIRE
Gain Therapeutics Reports Financial Results for Q3 2024 & Update
14 Nov 2024 //
GLOBENEWSWIRE
Gain Therapeutics Presents Data on DDR2 Inhibitors at EORTC
23 Oct 2024 //
GLOBENEWSWIRE
Gain Therapeutics Announces Presentation At EORTC-NCI-AACR Symposium
15 Oct 2024 //
GLOBENEWSWIRE
Gain To Present At Fox Foundation`s Parkinson`s Conference
09 Oct 2024 //
GLOBENEWSWIRE
Gain Therapeutics Presents GT-02287 Data At Neuroscience 2024
07 Oct 2024 //
GLOBENEWSWIRE
Gain Therapeutics to Participate at Upcoming Investor Conferences
03 Oct 2024 //
GLOBENEWSWIRE
Gain Therapeutics Presents GT-02287 Data At Parkinson`s Congress
30 Sep 2024 //
GLOBENEWSWIRE
Gain Therapeutics To Host Webinar On GT-02287 Study Results
26 Sep 2024 //
GLOBENEWSWIRE
Gain Therapeutics To Present GT-02287 Data At Neuroscience 2024
19 Sep 2024 //
GLOBENEWSWIRE
Gain Therapeutics to Attend H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
Gain Reports Phase 1 Win For Parkinson`s Drug
30 Aug 2024 //
FIERCE BIOTECH
Gain Therapeutics Announces Positive Phase 1 Results for GT-02287 in Parkinson’s
29 Aug 2024 //
GLOBENEWSWIRE
Gain Therapeutics Reports Q2 2024 Results And Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
01 Aug 2024 //
GLOBENEWSWIRE
Gain Therapeutics Completes Dosing In Phase 1 MAD Study For Parkinson`s
09 Jul 2024 //
GLOBENEWSWIRE
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
28 Jun 2024 //
GLOBENEWSWIRE
Gain Presents GT-02287 Data at FENS Forum 2024 Improvements in Cognitive
27 Jun 2024 //
GLOBENEWSWIRE
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
27 Jun 2024 //
GLOBENEWSWIRE
Gain to Present at H.C. Wainwright Neuro Perspectives Virtual Conference
25 Jun 2024 //
GLOBENEWSWIRE
Gain Therapeutics Prices $11M Public Offering
13 Jun 2024 //
GLOBENEWSWIRE
Gain Therapeutics Poster On Pipeline At FENS Forum 2024
30 May 2024 //
GLOBENEWSWIRE
Gain Therapeutics Reports Q1 2024 Results, Corporate Update
14 May 2024 //
GLOBENEWSWIRE
Gain`s GT-02287 Shows Positive Phase 1 Parkinson`s Results
24 Apr 2024 //
GLOBENEWSWIRE
Gain Appoints of Gene Mack as CFO
08 Apr 2024 //
GLOBENEWSWIRE
